Ranbaxy Laboratories has launched generic cevimeline hydrochloride capsules, used in treating Sjogren's syndrome, in the US market under an agreement with Daiichi Sankyo Inc.
New Delhi: Ranbaxy Laboratories has launched generic cevimeline hydrochloride capsules, used in treating Sjogren's syndrome, in the US market under an agreement with Daiichi Sankyo Inc.
Ranbaxy Pharmaceuticals Inc (RPI), a wholly-owned subsidiary of Ranbaxy Laboratories, has launched the authorised generic cevimeline hydrochloride 30 mg capsules in the US market, Ranbaxy said in a statement Tuesday.
Cevimeline hydrochloride is indicated for the treatment of symptoms of dry mouth associated with Sjogren's syndrome, an autoimmune disorder affecting the moisture-producing glands, and is presently distributed by Daiichi Sankyo Inc under the brand name Evoxac.
"This authorised generic form of Evoxac is an excellent example of optimising operational synergies that exists between Ranbaxy and Daiichi Sankyo, while accelerating our global business efforts," Ranbaxy CEO and Managing Director Arun Sawhney said.
According to IMS-MAT June 2012 data, Evoxac generated total annualised sales of USD 62.4 million in the US.
Commenting on the development Ranbaxy Chairman Tsutomu Une said: "We refer to the strategy of optimising diverse assets of both companies as our hybrid business model, that will allow both organisations to effectively seize opportunities across the full pharmaceutical value chain and product life-cycle, by leveraging the R&D and manufacturing of both Daiichi Sankyo and Ranbaxy."
RPI, based in Jacksonville, Florida, is a wholly-owned subsidiary of Ranbaxy Laboratories Ltd, and is engaged in the sale and distribution of generic and branded prescription products in the US healthcare system.
Shares of Ranbaxy Laboratories were trading at Rs 537.30 on the BSE in afternoon trade, up 1.75 percent from its previous close.